What is the recommended management of chronic kidney disease–mineral and bone disorder (CKD‑MBD) in patients with CKD stages 3‑5, including target laboratory values and pharmacologic therapy?

Management of CKD-MBD in Stages 3-5

Base all treatment decisions on serial assessments of phosphate, calcium, and PTH levels considered together, rather than single abnormal values, and aim to lower elevated phosphate toward normal range while avoiding hypercalcemia. 1

Laboratory Monitoring Strategy

CKD Stage 3a-3b (Non-dialysis)

• Measure calcium, phosphate, and PTH every 6-12 months initially
• Increase frequency if abnormalities develop or progress 1

CKD Stage 4 (Non-dialysis)

• Calcium and phosphate: every 3-6 months
• PTH: every 6-12 months 1

CKD Stage 5 (Non-dialysis)

• Calcium and phosphate: every 1-3 months
• PTH: every 3-6 months 1

CKD Stage 5D (Dialysis)

• More frequent monitoring based on treatment changes and biochemical trends 1

Target Laboratory Values

Phosphate

Lower progressively or persistently elevated phosphate toward the normal range (not a specific numeric target). Treatment decisions should be based on trends showing progressive or persistent elevation, not isolated values. 1

Calcium

• Adults: Avoid hypercalcemia at all costs
• Children: Maintain age-appropriate normal range
• Dialysis patients: Use dialysate calcium concentration between 1.25-1.50 mmol/L (2.5-3.0 mEq/L) 1

PTH Targets

CKD Stage 3a-5 (Non-dialysis):

• No optimal PTH target is known
• If PTH is progressively rising or persistently above the upper normal limit, first evaluate and correct modifiable factors:
  • Hyperphosphatemia
  • Hypocalcemia
  • High phosphate intake
  • Vitamin D deficiency 1

CKD Stage 5D (Dialysis):

• Maintain intact PTH at 2-9 times the upper normal limit for the assay
• Marked changes in either direction within this range should prompt treatment adjustment to prevent progression outside this range 1

Pharmacologic Management Algorithm

Step 1: Phosphate Management (CKD 3a-5D)

When to treat: Progressively or persistently elevated serum phosphate 1

Treatment approach:

1. Dietary phosphate restriction - Consider phosphate source (animal vs. vegetable vs. additives) when making recommendations 1
2. Phosphate binders - When diet alone is insufficient
   • Restrict the dose of calcium-based phosphate binders to minimize calcium load and vascular calcification risk 1
   • Consider non-calcium-based binders (sevelamer, lanthanum carbonate) as alternatives 2

Critical pitfall: Calcium overload from excessive calcium-based binders increases vascular calcification risk and mortality. Use the minimum effective dose. 1, 3

Step 2: PTH Management in Non-Dialysis CKD (3a-5)

Initial approach when PTH is elevated:

1. First, correct modifiable factors:

   • Reduce dietary phosphate intake
   • Administer phosphate binders if needed
   • Give calcium supplements if hypocalcemic
   • Supplement native vitamin D if deficient 1

2. If PTH remains progressively rising despite correction of modifiable factors:

   • Do NOT routinely use calcitriol or vitamin D analogs in CKD 3a-5 non-dialysis patients 1
   • Reserve calcitriol/vitamin D analogs for CKD Stage 4-5 with severe and progressive hyperparathyroidism only 1

Rationale: The 2017 KDIGO guidelines shifted away from routine vitamin D analog use in non-dialysis CKD due to concerns about hypercalcemia and hyperphosphatemia without proven mortality benefit. 1

Step 3: PTH Management in Dialysis (CKD 5D)

When PTH is elevated or rising in dialysis patients, use any of the following as first-line options (no single agent is prioritized): 1

• Calcimimetics (cinacalcet)
• Calcitriol
• Vitamin D analogs (paricalcitol, doxercalciferol)
• Combination therapy (calcimimetics + calcitriol or vitamin D analogs)

Important safety adjustments:

• If hypercalcemia develops: Reduce or stop calcitriol/vitamin D analogs (strong recommendation) 1
• If hyperphosphatemia develops: Reduce or stop calcitriol/vitamin D analogs 1
• If hypocalcemia develops: Reduce or stop calcimimetics depending on severity 1

Note on calcimimetics: While the EVOLVE trial did not meet its primary mortality endpoint, the guideline panel retained calcimimetics as an acceptable first-line option based on secondary analyses suggesting potential benefits. 1

Step 4: Surgical Management

Parathyroidectomy is indicated for:

• Severe hyperparathyroidism in CKD 3a-5D patients who fail to respond to medical/pharmacological therapy 1

Bone Health and Fracture Risk

CKD Stage 1-2

• Manage osteoporosis and fracture risk as for the general population (strong recommendation) 1

CKD Stage 3a-3b

• If PTH is in the normal range: Treat osteoporosis/fracture risk as for the general population 1

CKD Stage 3a-5D with Biochemical Abnormalities

• Treatment choices must account for:
  • Magnitude and reversibility of biochemical abnormalities
  • CKD progression rate
  • Consider bone biopsy to guide therapy 1

Critical consideration: In advanced CKD with active MBD abnormalities, standard osteoporosis treatments (bisphosphonates) may worsen adynamic bone disease. Correct biochemical abnormalities first before using anti-osteoporotic agents. 4

Key Clinical Pitfalls to Avoid

1. Treating single abnormal values - Always base decisions on trends in serial measurements 1

2. Excessive calcium loading - Restrict calcium-based phosphate binder doses; avoid hypercalcemia at all costs due to vascular calcification risk 1, 3

3. Routine vitamin D analog use in non-dialysis CKD - Reserve for severe, progressive hyperparathyroidism in CKD 4-5 only 1

4. Ignoring modifiable factors - Always correct hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency before escalating to calcitriol/analogs 1

5. Using bisphosphonates without correcting MBD - In CKD 3b-5, correct biochemical abnormalities first; bisphosphonates are generally safe only with eGFR >30 mL/min/1.73m² 4